Studies have also found that PPARG agonists improve insulin sensitivity and glucose tolerance in T2DM patients, reducing the need for β cell insulin secretion and hepatic glucose output and ultimately leading to improved glycaemic control [106]. Here, PPARG is linked to type 2 diabetes mellitus.